Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study
June 1999
in “
Clinical Therapeutics
”
TLDR Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
A study using data from the Proscar long-term efficacy and safety study found that finasteride is a cost-effective treatment for benign prostatic hyperplasia (BPH) compared to watchful waiting and terazosin over a 2-year period. Finasteride reduces the risk of acute urinary retention and surgery, resulting in cost savings. The study recommends finasteride as a viable option for BPH treatment.
View this study on clinicaltherapeutics.com →
Cited in this study
1 / results
research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
Related
3 / results
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia
Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.
research The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.